We are live on ! Find out more
ANTH

Anthera Pharmaceuticals, Inc.
ANTH

Delisted

ANTH was delisted on the 27th of June, 2018.

35 hedge funds and large institutions have $33.5M invested in Anthera Pharmaceuticals, Inc. in 2014 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more call options, than puts

Call options by funds: $147K | Put options by funds: $49K

33% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 6

22% more capital invested

Capital invested by funds: $27.4M → $33.5M (+$6.13M)

17% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 6

6% more funds holding

Funds holding: 3335 (+2)

100% less funds holding in top 10

Funds holding in top 10: 20 (-2)

Holders
35
Holders Change
+2
Holders Change %
+6.06%
% of All Funds
1.01%
Holding in Top 10
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
New
8
Increased
7
Reduced
6
Closed
6
Calls
$147K
Puts
$49K
Net Calls
+$98K
Net Calls Change
+$4K

ANTH Hedge Fund Activity: Q1 2014 in Review

35 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in Anthera Pharmaceuticals, Inc. (ANTH) for Q1 2014, worth a combined $33.5M — up 22% from $27.4M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new ANTH positions and 6 closed out — a net gain of 2 holders — while 7 added to existing stakes and 6 trimmed.

The largest buyer was Great Point Partners, opening a new position worth an estimated $4.35M. The largest seller was Sabby Management, cutting an estimated $3.26M.

  • 35 institutional investors held Anthera Pharmaceuticals, Inc. (ANTH) as of Q1 2014, up from 33 in Q4 2013.
  • Funds reported $33.5M of Anthera Pharmaceuticals, Inc. stock for Q1 2014, up 22% quarter-over-quarter.
  • 8 funds opened new Anthera Pharmaceuticals, Inc. positions in Q1 2014 and 6 closed out, a net change of +2 holders.
  • The largest Anthera Pharmaceuticals, Inc. buyer in Q1 2014 was Great Point Partners, an estimated $4.35M added.
  • The largest Anthera Pharmaceuticals, Inc. seller in Q1 2014 was Sabby Management, an estimated $3.26M sold.

Based on aggregated 13F filings for Q1 2014.